← Leaderboards
Virginia Eunice Kimonis
Southern Illinois University Sch Of Med
$4,585,544
Attributed
$5,935,423
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $807.2K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,135,584 · 20
FDA$1,799,839 · 1
By mechanism
R01$3,146,209 · 2
R21$1,521,382 · 4
R56$591,420 · 2
R03$475,002 · 2
K02$120,803 · 1
M01$80,607 · 10
Top collaborators
- Thomas E Lane3 shared
- Albert R La Spada3 shared
- Xiangmin Xu3 shared
Others in their field
Top investigators on “Osteitis Deformans”
- Conrad C Weihl · Washington University$7,176,230
- Nate Robinson · Iq Solutions, Inc.$5,191,215
- Matt Bowen · Iq Solutions, Inc.$4,617,968
- Kim Holmes · Iq Solutions, Inc.$4,365,676
- Edward Byung-Ha Lee · University Of Pennsylvania$3,109,658
- G David Roodman · University Of Texas Hlth Sci Ctr San Ant$2,946,667
Research focus
Osteitis DeformansGenesMyopathyMutationMuscle WeaknessMouse ModelMuscleMuscular DystrophyClinical ResearchHuman SubjectIn VitroSourceInclusion BodiesAutophagocytosisPathway InteractionsFamily GeneticsChromosomesAffectLinkage MappingPhenotypeInstitutionEvaluationGeneticGrant
Grant awards (36)
Mechanistic and Translational Investigations of HSPB8-associated dominant rimmed vacuolar myopathy$368,764
R21 · FY2024 · AR · contact PI
Engineered AAV vectors for combinatorial treatment of rare genetic brain diseases$599,924
R01 · FY2023 · FD
Antisense oligonucleotide treatment for Pompe disease$172,700
R21 · FY2023 · AR · contact PI
Engineered AAV vectors for combinatorial treatment of rare genetic brain diseases$599,938
R01 · FY2022 · FD
Antisense oligonucleotide treatment for Pompe disease$207,240
R21 · FY2022 · AR · contact PI
Engineered AAV vectors for combinatorial treatment of rare genetic brain diseases$599,977
R01 · FY2021 · FD
Preclinical Studies in Myopathy and ALS with VCP inhibitor CB5083$169,950
R21 · FY2020 · AR · contact PI
Preclinical Studies in Myopathy and ALS with VCP inhibitor CB5083$203,940
R21 · FY2019 · AR · contact PI
Translational Studies of Lipidomics-Associated Signaling Pathways in VCP Disease$154,500
R56 · FY2014 · AR · contact PI
High-fat diet rescues lethality of homozygous knock-in R155H VCP myopathic mice$176,507
R21 · FY2013 · AR · contact PI
High-fat diet rescues lethality of homozygous knock-in R155H VCP myopathic mice$222,281
R21 · FY2012 · AR · contact PI
PRADER-WILLI SYNDROME AND EARLY-ONSET MORBID OBESITY NATURAL HISTORY CLINICAL PR$1,726
M01 · FY2010 · RR · contact PI
CHARACTERIZATION OF FAMILIAL MYOPATHY, PAGET DISEASE OF BONE$690
M01 · FY2010 · RR · contact PI
INCLUSION BODY MYOPATHY ASSOPCIATED WITH APAGET DISEASE OF BONE AND FRONTOTEMPOR$345
M01 · FY2010 · RR · contact PI
Translational Studies in VCP Inclusion Body Myopathy with Paget Disease of Bone$436,920
R56 · FY2009 · AR · contact PI
PRADER-WILLI SYNDROME AND EARLY-ONSET MORBID OBESITY NATURAL HISTORY CLINICAL PR$7,927
M01 · FY2009 · RR · contact PI
GENETICS OF CRANIOSYNOSTOSIS$2,264
M01 · FY2009 · RR · contact PI
Genetic basis of myopathy with Paget disease of bone$245,052
R01 · FY2008 · AR · contact PI
PRADER-WILLI SYNDROME AND EARLY-ONSET MORBID OBESITY NATURAL HISTORY CLINICAL PR$916
M01 · FY2008 · RR · contact PI
Genetic basis of myopathy with Paget disease of bone$250,183
R01 · FY2007 · AR · contact PI
FOLIC ACID AND BETAINE FOR ANGELMAN SYNDROME$2,170
M01 · FY2007 · RR · contact PI
Genetic basis of myopathy with Paget disease of bone$284,789
R01 · FY2006 · AR · contact PI
FOLIC ACID AND BETAINE FOR ANGELMAN SYNDROME$7,384
M01 · FY2006 · RR · contact PI
CLINICAL GENETICS OF CRANIOSYNOSTOSIS$4,431
M01 · FY2006 · RR · contact PI
Genetic basis of myopathy with Paget disease of bone$291,392
R01 · FY2005 · AR
Characterization of Familial Myopathy &Paget Disease$81,000
R03 · FY2005 · AR
FOLIC ACID AND BETAINE FOR ANGELMAN SYNDROME$41,397
M01 · FY2005 · RR
Genetic basis of myopathy with Paget disease of bone$274,954
R01 · FY2004 · AR
Characterization of Familial Myopathy &Paget Disease$81,000
R03 · FY2004 · AR
FOLIC ACID AND BETAINE FOR ANGELMAN SYNDROME$11,357
M01 · FY2004 · RR
Characterization of Familial Myopathy &Paget Disease$80,875
R03 · FY2003 · AR
GENE CAUSING PAGET &LIMB-GIRDLE MUSCULAR DYSTROPHY$79,000
R03 · FY2003 · AR
GENE CAUSING PAGET &LIMB-GIRDLE MUSCULAR DYSTROPHY$79,000
R03 · FY2002 · AR
Clinical &Molecular Analysis of Neuromuscular Disorders$120,803
K02 · FY2001 · NS
GENE CAUSING PAGET &LIMB-GIRDLE MUSCULAR DYSTROPHY$40,415
R03 · FY2001 · AR
GENE CAUSING PAGET &LIMB-GIRDLE MUSCULAR DYSTROPHY$33,712
R03 · FY2001 · AR